Acutaas Chemicals Ltd

AGM notice and AR

• Notice for the 19th AGM scheduled Sept 24, 2026 at 11:30 IST via video conferencing.
• Annual Report for FY2025-26 considered and adopted.

Director re-appointments

• Ram Mohan Lokhande re-appointed as Whole-Time Director for 5 years from Feb 8, 2027.
• Term ends Feb 7, 2032; remuneration approved subject to shareholder approval.
• Anita Bandyopadhyay re-appointed as Non-Executive Independent Director for 5 years from Feb 8, 2027.
• Term ends Feb 7, 2032; subject to shareholder approval.

ESOS extension

• Extend Ami Organics ESOS 2023 to eligible employees of Indian subsidiaries.
• Subject to shareholder approval at the 19th AGM.

Capex plan Gujarat

• Capex up to ₹212 crore for a greenfield/brownfield plant in Gujarat.
• Capacity up to 81,000 MT per annum; existing NIL.
• Timeline by end FY2027-28.
• Funding via internal accruals or bank financing.
• Rationale: establish electronic-grade chemicals in Gujarat via company or subsidiary.

ECMS approval details

• Approval granted for ECMS incentive package for Acutaas's Electrolyte Additives manufacturing at Jhagadia, Gujarat.
• Date of communication: August 17, 2026.
• Cumulative investments: Rs 256.47 crore; eligible investment: Rs 119.12 crore.
• Incentive up to 25% of eligible investment during the benefit period to FY 2030-31.
• Incentive period valid for five years from Jan 27, 2026.

Meeting Details

• No meeting date, time, mode, or organizer information available in this excerpt.
• No company management participants or purpose details provided.

Consolidated results

• Consolidated revenue from operations: ₹32,967.48 lakhs; total income: ₹33,147.61 lakhs.
• Expenses: ₹22,756.60 lakhs; PBT: ₹10,391.01 lakhs; tax: ₹2,891.74 lakhs; PAT: ₹7,499.27 lakhs.
• Single segment: Custom synthesis and manufacturing of speciality chemicals.
• Limited Review on consolidated results reported with no modification.
• ACEPL stake diluted to 90% from 100% on May 19, 2026.
• CGST/CE inspection at Surat facility June 22–23, 2026; no material impact expected.

Standalone results

• Standalone revenue from operations: ₹32,240.92 lakhs; total income: ₹32,688.52 lakhs.
• Expenses: ₹22,287.02 lakhs; PBT: ₹10,401.50 lakhs; tax: ₹2,811.93 lakhs; PAT: ₹7,589.57 lakhs.
• Single segment: Custom synthesis for Pharmaceuticals API and others.
• Standalone results reviewed by auditors with unmodified report.

Financial results

• Board approved unaudited standalone and consolidated results for quarter ended June 30, 2026.
• Limited Review Report by Maheshwari & Co. Chartered Accountants submitted.

Meeting Details

• Date and time: Friday, July 24, 2026 at 4:00 PM IST.
• Mode/type: Earnings conference call, virtual.
• Organiser/event: Q1 FY27 Earnings Conference Call Invite organised by Nuvama Wealth Management.

Participants

• Chairman & Managing Director will participate.
• Chief Financial Officer will participate.
• President (Strategy) will participate.

Purpose

• Discuss unaudited Q1 FY27 results for quarter ended June 30, 2026.

Additional Notes

• Recording/presentation availability not stated.

Meeting Details

• Date: July 24, 2026; Location: Registered Office; Time not disclosed.

Key Agenda Items

• Unaudited standalone and consolidated financial results for first quarter ended June 30, 2026 to be considered and approved.
• Audit Committee Meeting on the same day preceding the Board meeting.

Other Notes

• Trading window closed from July 1, 2026; reopens 48 hours after unaudited results declaration.

Dematerialisation/rematerialisation status

• No dematerialisation/rematerialisation requests were received during the quarter ended 30 June 2026.
• No physical certificates were mutilated or cancelled as no requests were received.
• No substitution of the depository's name in the register of members was required.
• No listing actions occurred due to absence of dematerialisation requests.